Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Thus far, no manufacturing process able to support industrialization has been reported for the recombinant human brain-derived neurotrophic factor (rhBDNF). Here, we described the setup of a new protocol for its production in () and its purification to homogeneity. A synthetic gene, codifying for the neurotrophin precursor, was inserted into an expression vector and transformed into BL21 (DE3) strain. The recombinant protein accumulates, at high yields, into inclusion bodies. With the developed strategy, more than 50% of the precursor can be refolded. The protein is successively digested by trypsin and the rhBDNF mature form is finally purified by two additional chromatographic steps If the wild-type precursor can be efficiently obtained by the proposed methodology, its pro-peptide remotion, through enzymatic digestion, is however problematic. To circumvent this difficulty, the precursor hinge region, containing the natural furin recognition site, was engineered to be more specifically cleaved by trypsin. Notwithstanding the substitution of three residues in the pro-region carboxyterminal, the precursor correctly refolds and is efficiently cleaved to generate a biologically active mature rhBDNF. This efficient high-yield process fills the current need of a scalable protocol to produce GMP-grade material and unlocks the rhBDNF employment in future clinical investigations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11678288PMC
http://dx.doi.org/10.3390/ijms252413425DOI Listing

Publication Analysis

Top Keywords

recombinant human
8
human brain-derived
8
brain-derived neurotrophic
8
neurotrophic factor
8
precursor
5
efficient production
4
production recombinant
4
factor engineering
4
engineering pro-region
4
pro-region manufacturing
4

Similar Publications

Bietti crystalline dystrophy (BCD) is an autosomal recessive disorder caused by loss-of-function mutations in the gene, characterized by crystal-like lipid deposits in the retina, progressive photoreceptor loss, and retinal pigment epithelium (RPE) deterioration. Currently, there are no approved treatments for BCD. VGR-R01, an investigational gene therapy, uses subretinal administration of recombinant adeno-associated virus type 8 (AAV8) vector to deliver the human CYP4V2 gene.

View Article and Find Full Text PDF

Introduction: Human papillomavirus (HPV) infection has been implicated in autoimmune processes, yet concerns remain about the potential autoimmune risks of HPV vaccination. Juvenile idiopathic arthritis (JIA) is a chronic autoimmune condition that typically manifests in childhood. The relationship between HPV vaccination and the development of JIA remains uncertain.

View Article and Find Full Text PDF

Background: Recombinant human thrombopoietin (rhTPO) regulates platelet production by promoting megakaryocyte proliferation and has shown promising therapeutic effects in hematopoietic recovery for severe aplastic anemia (SAA). However, its potential impact on immune cells remains unclear.

Methods: This study included 23 patients with SAA, who were divided into two groups based on whether they received rhTPO.

View Article and Find Full Text PDF

Background: In contrast-enhanced digital mammography (CEDM) and contrast-enhanced digital breast tomosynthesis (CEDBT), low-energy (LE) and high-energy (HE) images are acquired after injection of iodine contrast agent. Weighted subtraction is then applied to generate dual-energy (DE) images, where normal breast tissues are suppressed, leaving iodinated objects enhanced. Currently, clinical systems employ a dual-shot (DS) method, where LE and HE images are acquired with two separate exposures.

View Article and Find Full Text PDF

Construction of a bacterial surface display system using split green fluorescent protein (GFP) in Escherichia coli.

Biotechnol Lett

September 2025

Department of Chemical Engineering, Hongik University, Sangsu-dong, Mapo-gu, Seoul, 04066, Republic of Korea.

The cell surface display system employs carrier proteins to present target proteins on the outer membrane of cells. This system enables functional proteins to be exposed on the exterior of living cells without cell lysis, allowing direct interaction with the surrounding environment. A major limitation of conventional approaches is the difficulty in displaying large-sized enzymes or antibodies, despite their critical roles in applications requiring functional domains that must remain intact, such as catalytic or antigen-binding sites.

View Article and Find Full Text PDF